FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Bipartisan Bill to Curb Investment in Chinas Biotech Sector

U.S. House lawmakers introduce bipartisan legislation aimed at expanding federal scrutiny of U.S. investments in China's biotechnology sector, arguing...

Pazdur Recommends Restructuring FDA

Former FDAers Richard Pazdur and Nicole Gormley promote ways to restructure the agency so it can be more independent and successful.

latest-news-card-1
Human Drugs

Diamantas Tries to Win Back Rare Disease Advocates

FDA acting commissioner Kyle Diamantas, who is rumored to be under consideration to be named commissioner, meets with rare disease community advocates...

latest-news-card-1
Human Drugs

Faulty Drug Supply Chain Hurts Seniors: Hearing

The Senate Special Committee on Aging hears testimony on how an unsecure U.S. drug supply chain is harming older patients.

latest-news-card-1
Human Drugs

FDA Accepts 1st Drug-Induced Liver Injury Tool

FDA has accepted a Letter of Intent for the first in silico artificial intelligence-driven digital liver model for predicting drug-induced liver injur...

latest-news-card-1
Human Drugs

FDA Accepts Roche NDA for Breast Cancer Drug

FDA accepts for priority review a Roche NDA for giredestrant, an investigational oral endocrine therapy for patients with early-stage estrogen recepto...

latest-news-card-1
Marketing

FDA Cites QOL Medical for Misleading Promotion of Sucraid

FDA issues an untitled letter to QOL Medical, alleging that promotional emails for its rare-disease therapy Sucraid (sacrosidase) Oral Solution were f...

latest-news-card-1
Federal Register

FDA Warns Brazilian Drug Maker Over Records Request

FDA sends a Warning Letter to Brazilian over-the-counter drug manufacturer Aeroflex Industria de Aerosol after the company failed to respond to multip...

latest-news-card-1
Human Drugs

HealthPartners Neuroscience Center BIMO Issues

FDA warns St. Paul, MN-based HealthPartners Neuroscience Center Research and Innovation about good laboratory practice violations in its conduct of no...

latest-news-card-1
Human Drugs

3-Year New Clinical Investigation Exclusivity Guidance Explained

Two Morgan Lewis attorneys explain a new FDA draft guidance on three-year drug exclusivity for new clinical investigations.